Les biothérapies en médecine interne (à propos de 20 cas)
| dc.contributor.advisor | Mohammed Karim Moudden | |
| dc.contributor.author | Fatima Zahlou | |
| dc.date.accessioned | 2023-09-19T15:06:47Z | |
| dc.date.accessioned | 2026-01-28T15:15:19Z | |
| dc.date.available | 2023-09-19T15:06:47Z | |
| dc.date.issued | 2020 | |
| dc.description.collaborator | Ali Zinebi | |
| dc.description.collaborator | Hicham Eddou | |
| dc.description.collaborator | Hicham Kechna | |
| dc.identifier.uri | https://toubkal.imist.ma/handle/123456789/24574 | |
| dc.identifier.uri | https://doi.org/10.83129/toubkal-17761 | |
| dc.language.iso | FR | |
| dc.publisher | Faculté de Médecine et de Pharmacie, Fès | fr_FR |
| dc.subject | Biothérapie | fr_FR |
| dc.subject | Rituximab | fr_FR |
| dc.subject | anti-TNF alpha | fr_FR |
| dc.subject | Tocilizumab | fr_FR |
| dc.subject | maladie systémique | fr_FR |
| dc.subject.other | Médecine | |
| dc.subject.specific | Médecine interne | |
| dc.title | Les biothérapies en médecine interne (à propos de 20 cas) | fr_FR |
Files
Original bundle
1 - 1 of 1